Search clinical trials for: High Risk Factors

Total 57715 results

Lebanese University
Hospital Saydet Zgharta University Medical Center

Recruiting

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (LUSZ_AVIST)

COVID-19 | Hospitalized COVID-19 Patients

Lebanon
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Peking Union Medical College Hospital

Recruiting

Risk Factors for Prolonged Mechanical Ventilation in Elevated Mean Airway Pressure

Intensive Care Unit | Mechanical Ventilation Pressure High

China
Fudan University

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Diffuse Large B Cell Lymphoma

China
Mackay Memorial Hospital

Recruiting

Early Identification of Heart Failure in a High-Risk Diabetic Cohort

Type2diabetes

Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Tianjin Medical University Second Hospital

Recruiting

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation

China
Jennifer Crombie, MD
Genentech, Inc.

Recruiting

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Lymphoma | Lymphoma, Large B-Cell, Diffuse

United States
Sultan Qaboos University
Ministry of Higher Education, Research and Innovation

Not yet recruiting

The Impact of Using a Smartphone Health Application in the Improvement of Cardiovascular Disease Risk Factors

Hypertension | Obesity | Diabetes Mellitus | Hypercholesterolemia
M.D. Anderson Cancer Center
Sanofi

Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Greece, Denmark, Slovakia
Rio de Janeiro State University

Recruiting

Glycemic Patterns After Bariatric Surgery and High Glycemic Variability and Hypoglycemia Unawareness Risk Factors

Bariatric Surgery

Brazil
Second Affiliated Hospital, School of Medicine,...
Shaoxing People's Hospital; Shaoxing Second Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Multiple Myeloma

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
Kite, A Gilead Company

Recruiting

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

High-risk Large B-cell Lymphoma (LBCL)

United States, Austria, Spain, Italy, Australia, Germany, Netherlands, Canada, Portugal, United Kingdom, France
Joseph Tuscano
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Peking University Cancer Hospital & Institute
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

B-cell Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Puerto Rico
Novartis Pharmaceuticals

Recruiting

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera (Prospero)

Polycythemia Vera

Italy
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BL-PDT-RCT)

Non-muscle-invasive Bladder Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Multiple Myeloma | ISS Stage III Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Kite, A Gilead Company; Acerta Pharma, LLC

Recruiting

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
The Hospital for Sick Children
McMaster University; Unity Health Toronto; University of Toronto; Queen Mary University... and other collaborators

Not yet recruiting

Nutrition Recommendation Intervention trialS in Children's Healthcare (NuRISH)

Diabetes | Obesity, Childhood | Health Risk Behaviors | Nutrition | Breastfeeding | Exclusive Breastfeeding
Irene Ghobrial, MD
Janssen Research & Development, LLC

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Sichuan University

Recruiting

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Myelodysplastic Syndrome | Allogeneic Hematopoietic Stem Cell Transplantation | Conditioning

China
Massachusetts General Hospital
American Foundation for Suicide Prevention

Recruiting

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

Major Depressive Disorder

United States
Peking Union Medical College Hospital

Recruiting

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
The Hospital for Sick Children
Thalassemia Foundation of Canada

Recruiting

Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

Thalassemia in Children

Canada
Children's Hospital Los Angeles
United Therapeutics

Recruiting

Rapid Administration Pilot for Infusing Dinutuximab (RAPID)

Neuroblastoma

United States
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Li Zhiming
Antengene Corporation

Recruiting

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

DLBCL Germinal Center B-Cell Type

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Recurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma

United States
Catharina Ziekenhuis Eindhoven
ZonMw: The Netherlands Organisation for Health Research and Development; Stichting... and other collaborators

Recruiting

Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment (PRedICT-TOPIC)

Cervical Intraepithelial Neoplasia | CIN 2/3 | Cervical Intraepithelial Neoplasia Grade 2/3 | Cervical High Grade Squamous Intraepithelial Lesion

Netherlands
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes | Myeloproliferative Chronic Myelomonocytic Leukemia

United States
Sun Yat-sen University
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Mansoura University

Recruiting

Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients

Non-Muscle Invasive Bladder Cancer

Egypt
German Cancer Research Center

Recruiting

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Early-stage Breast Cancer

Germany
National Cancer Institute (NCI)

Recruiting

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

United States

Search clinical trials for: High Risk Factors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations